首页> 外文OA文献 >Novel bisnaphthalimidopropyl (BNIPs) derivatives as anticancer compounds targeting DNA in human breast cancer cells.
【2h】

Novel bisnaphthalimidopropyl (BNIPs) derivatives as anticancer compounds targeting DNA in human breast cancer cells.

机译:新型双萘二甲酰亚胺基丙基(BNIPs)衍生物作为靶向人类乳腺癌细胞中DNA的抗癌化合物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bisnaphthalimidopropyl (BNIP) derivatives are a family of compounds that exert anti-cancer activities in vitro and, according to previous studies, variations in the linker sequence have increased their DNA binding and cytotoxic activities. By modifying the linker sequence of bisnaphthalimidopropyl diaminodicyclohexylmethane (BNIPDaCHM), a previously synthesised BNIP derivative with anti-cancer properties, three novel BNIP derivatives were designed. Bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), a structural isomer of BNIPDaCHM, bisnaphthalimidopropyl ethylenedipiperidine dihydrobromide (BNIPPiEth), an isoform of BNIPDaCHM with a shorter linker chain, and (trans(trans))-bisnaphthalimidopropyl diaminodicyclohexylmethane (trans,trans-BNIPDaCHM), a stereoisomer of BNIPDaCHM, were successfully synthesised (72.3?29.5% yield) and characterised by nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS). Competitive displacement of ethidium bromide (EtBr) and UV binding studies were used to study the interactions of BNIP derivatives with Calf Thymus DNA. The cytotoxicity of these derivatives was assessed against human breast cancer MDA-MB-231 and SKBR-3 cells by MTT assay. Propidium iodide (PI) flow cytometry was conducted in order to evaluate the cellular DNA content in both breast cancer cell lines before and after treatment with BNIPs. The results showed that all novel BNIPs exhibit strong DNA binding properties in vitro, and strong cytotoxicity, with IC50 values in the range of 0.2-3.3 mM after 24 hours drug treatment. Two of the novel BNIP derivatives, BNIPPiEth and trans,trans-BNIPDaCHM, exhibited greater cytotoxicity against the two breast cancer cell lines studied, compared to BNIPDaCHM. By synthesising enantiopures and reducing the length of the linker sequence, the cytotoxicity of the BNIP derivatives was significantly improved compared to BNIPDaCHM, while maintaining DNA binding and bis-intercalating properties. In addition, cell cycle studies indicated that trans,trans-BNIPDaCHM, the most cytotoxic BNIP derivative, induced sub-G1 cell cycle arrest, indicative of apoptotic cell death. Based on these findings, further investigation is under way to assess the potential efficacy of trans,trans-BNIPDaCHM and BNIPPiEth in treating human breast cancer.
机译:双萘二甲酰亚胺基丙基(BNIP)衍生物是一类在体外发挥抗癌活性的化合物,根据以前的研究,接头序列的变化增加了其DNA结合和细胞毒活性。通过修改双萘二甲酰亚胺丙基二氨基二环己基甲烷(BNIPDaCHM),一种先前合成的具有抗癌特性的BNIP衍生物的接头序列,设计了三种新型的BNIP衍生物。双萘二甲酰亚胺基丙基-哌啶基丙烷(BNIPPiProp),BNIPDaCHM的结构异构体,双萘二甲酰亚胺丙基乙二哌啶二氢溴化物(BNIPPiEth),具有较短接头链的BNIPDaCHM异构体和(反式(反式))-双萘二甲酰基甲基-N,N-甲基,N-甲基,N-甲基成功地合成了BNIPDaCHM的BNIPDaCHM(收率72.3%至29.5%),并通过核磁共振波谱(NMR)和质谱(MS)进行了表征。竞争性溴化乙锭(EtBr)的取代和UV结合研究用于研究BNIP衍生物与小牛胸腺DNA的相互作用。通过MTT分析评估了这些衍生物对人乳腺癌MDA-MB-231和SKBR-3细胞的细胞毒性。进行碘化丙啶(PI)流式细胞术以评估在用BNIP治疗前后两种乳腺癌细胞系中细胞DNA的含量。结果表明,所有新的BNIPs在体外均具有很强的DNA结合特性,并具有很强的细胞毒性,经过24小时药物治疗,IC50值在0.2-3.3 mM之间。与BNIPDaCHM相比,两种新型BNIP衍生物BNIPPiEth和trans,trans-BNIPDaCHM对所研究的两种乳腺癌细胞系表现出更大的细胞毒性。通过合成对映体并减少接头序列的长度,与BNIPDaCHM相比,BNIP衍生物的细胞毒性得到了显着改善,同时保持了DNA结合和双插入特性。此外,细胞周期研究表明,最具细胞毒性的BNIP衍生物反式,反式-BNIPDaCHM诱导了sub-G1细胞周期停滞,表明细胞凋亡。基于这些发现,正在进行进一步的研究以评估反式,反式-BNIPDaCHM和BNIPPiEth在治疗人类乳腺癌中的潜在功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号